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Peroxisome proliferator-activated receptors (PPARs) have been demonstrated to have a role in immune regulation. In general, they
are anti-inflammatory and promote Th2 type responses, and they are associated with the alternative activation of macrophages.
Interestingly, helminth infections, such as the schistosome blood flukes that cause schistosomiasis, are characterised by a Th2
response and the accumulation of alternative activated macrophages. This would suggest that at some level, PPARs could have a
role in the modulation of the immune response in schistosomiasis. This paper discusses possible areas where PPARs could have a
role in this disease.
1. Introduction
The peroxisome proliferator-activated receptors (PPARs) are
a group within the 48 transcription factors of the nuclear
hormone receptor family involved in lipid metabolism and
inflammation [1]. To be transcriptionally active, they require
hetrodimerisation with the retinoid X receptor (RXR) to
which the resulting heterodimers bind with peroxisome
proliferator-response elements (PPREs) on DNA after acti-
vation by a ligand-to-modulate transcription [2]. The PPREs
are located at the 5′ end of the target gene and consist of
a repeat sequence—AGGTCA—separated by one nucleotide
[3]. The binding to the PPRE is orientated with PPAR at the
5′ end and RXR towards the 3′ end [2]. For transcriptional
control to occur, the PPAR/RXR heterodimers have to
interact with coactivators or suppressors for stimulation
or inhibition of target-gene expression, respectively [2].
The PPARs can also block transcription of other genes
by interacting with other transcription factors by non-
genomic transrepression, whereby they inhibit transcription
by preventing dissociation of corepressors or sequester co-
activators needed for binding of the transcription factor to
the DNA [4]. There are 3 isoforms of the PPAR receptors,
PPARα, PPARβ/δ, and PPARγ [5]. PPARα is expressed in the
liver, brown fat, heart, and skeletal muscle which have high
levels of fatty acid catabolism, while PPARγ is expressed in
adipose tissue, the colon, and in macrophages, it is the major
regulator in adipocyte diﬀerentiation and is a determinant
in insulin sensitivity [3]. PPARβ/δ is ubiquitously expressed
and is thought to have a role in metabolic disorders [3].
Polyunsaturated fatty acids and eicosanoids act as natural
ligands for these receptors; however, synthetic ligands exist
such as fibrates that target PPARα and the thiazolidinediones
that target PPARγ [3].
PPARS have been demonstrated to be important in a
number of diﬀerent disease states such as metabolic disorders
[3], inflammation [6], malaria [7], Chagas disease [8], and
leishmaniasis [9]. Recent studies have revealed a role for
PPARs in the control of the immune response. In general,
they are anti-inflammatory [10], promote the development
of alternatively activated macrophages (AAMΦ) [11], and are
Th2 biasing [12]. Helminth worms have an incredible ability
to modulate the host immune response and, in general,
promote a Th2-biased environment that commonly involves
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the generation of AAMΦs [13], as occurs during schistosome
infection. The fact that this parasite and other helminths
induce Th2 biasing, with accumulation of AAMΦs, suggests
that at some level, PPARs could be involved. This paper
will explore the current state of knowledge in this area,
focusing on the role of PPARs in the immunopathology
of schistosomiasis and their potential as novel therapeutic
targets.
2. Immune Regulation in Schistosomiasis
Schistosomiasis is a major health problem responsible for
significant morbidity and mortality worldwide. It is esti-
mated that approximately 200 million people are infected,
causing severe disease in 20 million people [14]. The disease
is caused by infection with the trematode worms, the
schistosomes, of which Schistosoma mansoni, S. japonicum,
and S. haematobium are the most important in regards
to human disease [15]. Pathology is associated with the
host’s immune response to the eggs which results in a
granulomatous reaction [16]. Helminth parasites are able
to modulate the host immune response, allowing them to
have good longevity within the mammalian host. Helminth
infections are noted for polarising the immune response
more towards a Th2 response characterised by interleukin
(IL)-4, 5, and 13, large amounts of IgE, and by CD4+
T cells [17]. In schistosomiasis, the immune response is
characterised by a switch from an early proinflammatory
Th1 response to a Th2 response to eggs released by the
female worm [18]. The Th2 response has the characteristics
described above and is associated with AAMΦs ([19–21]).
Cytokines such as INF-γ, IL-2, IL-12, and TNF-α are
associated with the early Th1 response and are repressed
during this switch [18]. Helminth parasites can achieve
this modulation the by release of soluble factors which can
interact with host immune cells [13]. There is good evidence
for this in schistosome infections in which both live or dead
eggs injected into naive mice rapidly induce a Th2 response
[20]. Egg-derived products have been observed to drive the
switch from the Th1 response to the Th2 response. Examples
of this are the IL-4-inducing principal of S. mansoni eggs
(IPSEs) that is secreted from the egg subshell into the
surrounding granuloma area and has been demonstrated
to induce human basophils to produce IL-4 and IL-13
[22]. Similarly, the glycoprotein, omega-1 that is secreted
by S. mansoni eggs and present in secreted egg antigen
(SEA), has been observed to drive human monocyte-derived
dendritic cells towards Th2 polarisation and to generate Th2
responses in vivo in mice [23]. Egg-derived glycoconjugates,
α3-fucosyltransferase, and core g 2-xylosyltransferase have
been used with dendritic cells to produce a Th2 response
in the murine model of disease caused by S. mansoni
[24].
3. Immune Regulation by PPARs
It is believed that PPARs may be important in the regulation
of the immune response, a role supported by the fact that
PPARs have been described in monocytes, macrophages,
neutrophils, peripheral blood lymphocytes, T cells, B cells,
natural killer cells, dendritic cells, eosinophils, and mast cells
[1]. Supporting this, ligands of PPARs have been shown to
have a therapeutic role in several models of inflammatory
and autoimmune diseases [6]. PPARγ agonists have been
demonstrated to have anti-inflammatory eﬀects in renal
injury [25], murine carotid atherosclerosis [26], and in
oxidative stress induced in a human diploid fibroblast model
of aging [27]. PPARβ/δ agonists have additionally been
demonstrated to have a protective role in a murine model
of autoimmune encephalomyelitis [28]. Further, PPARγ
agonists have been observed to inhibit the production of
TNF-α in human monocytes [10].
Part of the anti-inflammatory mode of action of PPARs
is due to the fact they can interact with transcription factors
involved in inflammation such as NF-κB, activator protein-1
(AP-1), and signal transducers and activators of transcription
(STAT) at a transcriptional level ([29, 30]). In the case of
NF-κB and AP-1, PPARα has been shown to interact directly
with p65, c-Jun, and CBP, thereby interfering with their
transcriptional capacity [29], while the PPARγ agonist, 15d-
PGJ2, inhibits STAT signalling indirectly [30]. Interference
of these pathways results in the downregulation of the Th1
proinflammatory cytokines TNF-α, IL-1, -6, and 12 ([29,
30]).
Notably, PPARs have been demonstrated to result in
upregulation of Th-2 responses and downregulation of Th-
1 responses. An agonist of PPARα, gemfibrozil, results in
increased number of GATA3 positive T cells in the spleens
of donor mice as well as the stimulation of its expression
and DNA-binding activity resulting in IL-4 production [12].
In the same study, gemfibrozil was additionally observed
to inhibit the expression and DNA-binding activity of T-
bet, causing a decrease in INF-γ production. IL-4 can
interact with PPARγ indirectly and directly in macrophages
[31]. PPARγ expression is both directly and indirectly
upregulated by IL-4. IL-4 will induce target-gene expression
by increasing PPARγ expression and by increasing the
production of PPARγ ligands via 15-lipoxygenase, which
results in lipoperoxidation products such as linoleic acid
(HODE) or arachidonic acid (HETE) [31]. Schistosomes
and other helminths could potentially interact with PPARs
through these pathways. They could do this indirectly
via IL-4 and IL-13 as both cytokines can activate PPARγ
resulting in the suppression of the proinflammatory response
and activation of AAMΦs which favour the establishment
of a chronic parasite infection [1]. Schistosomes could
potentially interact with PPARs via hemozoin. Schistosomes
produce hemozoin as a product from feeding on mam-
malian host red blood cells; its structure is identical to
malarial hemozoin [1]. It is composed of a complex mixture
of neutral lipids and polyunsaturated lipids from which
lipoperoxidation products HETE and HODE acid, which
are natural ligands for PPAR [1], are derived (Figure 1).
Carter et al. [32] showed that macrophages that have
previously phagocytosed schistosomal-derived hemozoin
have a reduced ability to produce iNOS in response to
LPS.
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Figure 1: Summary of possible interactions in schistosomiasis with PPARs. This figure displays the possible pathways in which PPARs could
be involved in schistosomiasis. PPARs could be involved in immune regulation, as they are associated in generation of a Th2 response.
PPARβγ/α both cause downregulation of Th1 cytokines and promote IL-4/-13 production. PPARs have a role in the alternate activation of
macrophages where PPARγ/α have been demonstrated to be essential for this process. In schistosomiasis, AAMΦs have a protective eﬀect
and a role in Th2 biasing. Schistosomes could interact with this activation indirectly via induction of IL-4/-13 production and directly
by the breakdown products of hemozoin, which can interact with PPARγ/α. In terms of pathology, the PPARs could interact with the
transdiﬀerentiation process of HSCs into fibrogenic myofibroblasts. They could limit this process by inhibiting transdiﬀerentiation associated
with increased PPARγ, whereas PPARα would be associated with generation of the fibrogenic myofibroblast.
4. PPARs and Alternatively
Activated Macrophages
Macrophages have multiple roles with regards to the host
immune response. They have a role in early detection of
invading pathogens, both as antigen presenting cells (APCs)
that initiate a host response and as eﬀecter cells that can
act to kill the invading pathogen [33]. Macrophages used to
be classified as either activated or deactivated, but in recent
years, this has changed to classically activated macrophages
(CAMΦ) and AAMΦs [33]. CAMΦs are induced by INF-
γ, TNF-α, and LPS and produce proinflammatory cytokines
such as IL-1β, IL-12, IL-23, and TNF-α and the chemokines
CXCL-9, -10, -11, and -16 [33]. AAMΦs are associated
with production of IL-10 and are induced by IL-4 and IL-
13 [33]. This classification has been expanded in recent
years with proinflammatory macrophages being termed M1,
while anti-inflammatory macrophages are termed M2. The
M2 macrophages have been divided into diﬀerent subsets,
whereby AAMΦs are classified as M2a cells which are defined
by low expression levels of IL-12 [34], or are M2b cells,
which release high levels of IL-10 on activation by immune
complexes, and M2c cells which are induced by IL-10 and are
believed to be more similar to CAMΦ [33]. One of the main
diﬀerences distinguishing AAMΦs from CAMΦs is in how
they metabolise L-arginine. CAMΦ metabolise L-arginine
into NO via iNOS, while AAMΦ metabolise L-arginine into
urea and L-ornithine via arginase-1 (arg-1) [35].
AAMΦ have been associated with many helminth infec-
tions with many diﬀerent roles attributed to them. In
infection with the nematode Brugia malayi, AAMΦs are
associated with Th-2 biasing [36, 37], while in infection with
Heligmosomoides polygyrus, AAMΦs have a role in parasite
clearance and host protection [38]. In cestode infections,
AAMΦs have been associated with downregulation of the
immune response in Echinococcus multilocularis [39] and Th-
2 biasing in Taenia crassiceps infection as well as favouring
parasite survival [40]. In Schistosoma infection, they have
a role in Th-2 biasing as well as in downregulation of the
Th-1 response and mediate immunopathology promoting
host protection, but, at the same time, they promote
progressive pathology due to granuloma formation ([21,
41]). Overall, their role seems to be host protective by causing
downregulation of overaggressive inflammatory reactions,
but they are also protective for the parasite, forming part
of the immunomodulation strategy needed for successful
colonisation of the host.
PPARs could potentially have a role in helminth infec-
tions by regulating AAMΦs. There are a number of studies
demonstrating PPARγ as essential for AAMΦ activation and
maturation in other disease states such as metabolic syn-
drome and leishmaniasis ([9, 11]). In metabolic syndrome, it
has been shown with macrophage-specific PPAR-γ knockout
mice that PPARγ is essential for AAMΦ maturation resulting
in the mice developing diet-induced obesity, insulin resis-
tance, and glucose intolerance [11]. Additionally, PPARγ and
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PPARδ agonists have been observed to mediate arginase-1
expression in macrophages, and this expression is blocked
in macrophages from PPARγ- and PPARδ-deficient mice
[11]. Interactions between IL-4/13 and PPARs have been
extensively studied in leishmaniasis in which PPARs promote
AAMΦ-mediated susceptibility to the disease by stimulating
intracellular amastigote growth in infected macrophages
[11]. This is due to the lack of NO production in resultant
AAMΦ which is essential for amastigote killing.
5. DO PPARs Modulate Host Pathology?
The hepatic stellate cell (HSC) is located within the liver
sinusoid in the space of Disse where it is responsible
for storage of vitamin A and the maintenance of a low-
density matrix between the liver endothelium cells and the
hepatocytes [42]. Maintenance of this matrix is important
as it allows solutes in the plasma to reach the hepatocytes
unimpeded, allowing the liver to function correctly [43].
In response to insult or injury to the liver, HSCs can
undergo a process of transdiﬀerentiation from the quiescent
vitamin A-storing cell to a myofibroblast responsible for the
accumulation of scar tissue within the space of Disse [44].
This has highlighted parallels between this cell type and that
of the adipocyte which can undergo a similar process [45].
Adipocytes diﬀerentiate from a fibroblast-like preadipocyte
and become lipid laden associated with the expression of
PPARγ [46]. Quiescent HSCs express PPARγ which upon
transdiﬀerentiation into a myofibroblast-like cell lose their
ability to store lipid droplets as the expression and activity of
PPARγ decrease [47]. This has suggested a role for PPARγ
agonists in the treatment of fibrosis. PPARγ agonists have
been demonstrated to cause reversion of the myofibroblast
back into a quiescent HSC ([45, 47]).
Recent studies have implicated a role for HSCs in the
pathogenesis of schistosomiasis [48]. Activated HSCs have
been observed in the murine model of disease and at the end
stage of human disease with S. japonicum [49] and human
disease with S. mansoni [50]. Notably, the PPARγ agonist
rosiglitazone has been demonstrated to prevent fibrosis in
S. japonicum infection of mice [51]. In this study, mice
cotreated with the antischistosome drug praziquantel and
rosiglitazone induced reduced expression of collagen 1 and
3, α smooth muscle actin (a marker for myofibroblasts),
inflammation, increased expression of PPARγ, reduced NF-
κB-binding activity, and reduced TNF-α levels [51]. In a
recent study, Anthony et al. [52] showed that eggs of S.
mansoni could downregulate fibrogenesis in the human
HSC cell line, LX-2, causing regression from the activated
myofibroblast to the quiescent HSC. This downmodulation
was associated with increased expression of PPARγ at the
gene level as well as with the accumulation of lipid droplets
within the cytoplasm of HSCs. At the granuloma level,
fibrosis first occurs towards the periphery of the granuloma
site, and it was postulated in this study that antigens from
the egg may inhibit fibrosis in close proximity to the egg as
it is not until the egg is killed and destroyed that fibrosis
occurs throughout the granuloma area. However, PPARγ
could act as a double-edged sword, as it would be involved in
alternative activation of macrophages at the granuloma site,
which in turn can be responsible for collagen production by
the production of arginase-1 which promotes the production
of proline. Additionally, the Th2 response is profibrogenic
and high levels of IL-13 are associated with fibrosis in
schistosomiasis [53].
6. Conclusions
Schistosomiasis is characterised by a switch from an early
Th1 response to a Th2 response and accumulation of
AAMΦs in response to eggs released by the schistosome
worms. PPARs have been demonstrated to cause downreg-
ulation of proinflammatory Th1 cytokines while simultane-
ously upregulating Th2 responses. They have additionally
been shown to be essential in the alternative activation of
macrophages. This suggests that PPARs may play a role in
the regulation of the host response to schistosome antigens.
Additionally, it has been demonstrated that S. mansoni
eggs cause downregulation of fibrogenesis in the human-
derived HSC cell line, LX2, a response associated with
increased expression of PPARγ, and accumulation of lipid
droplets within the cell’s cytoplasm. Rosiglitazone, a PPARγ
ligand, has been additionally been demonstrated to reduce
pathology associated with S. japonicum infection in mice.
The possible interactions with schistosomiasis and PPARs
are summarised in Figure 1. Further studies of the role of
PPARs in this disease and those caused by other helminth
infections are, therefore, warranted and may help in the
identification of new antipathology drug and vaccine targets
for schistosomiasis and other important diseases caused by
the parasitic helminths.
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